Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
On March 8, 2023, Allergan Aesthetics, part of AbbVie (NYSE: ABBV), announced a partnership with IFundWomen to support women entrepreneurs on International Women's Day. The initiative provides 20 grants of $25,000 each along with a year of coaching and mentorship to help close the 'Confidence Gap' in business. Women entrepreneurs face significant funding disparities, receiving only about 2% of venture capital, impacting their growth potential. Applications are open until April 7, 2023, with recipients announced in June 2023. The program aims to empower future women leaders by providing essential resources for success.
AbbVie (NYSE: ABBV) will present at the Barclays Global Healthcare Conference on March 15, 2023, at 12:35 p.m. Central time. Key executives including Robert A. Michael and Scott Reents will be featured in the presentation. A live audio webcast will be available on AbbVie's Investor Relations website, with an archived version accessible later the same day. AbbVie is focused on innovative therapies across multiple therapeutic areas, such as immunology and oncology. For more details, visit www.abbvie.com.
AbbVie (NYSE: ABBV) will present at the Cowen 43rd Annual Health Care Conference on March 7, 2023, at 8:10 a.m. Central time. Key executives, including Robert A. Michael, Scott Reents, Jeffrey R. Stewart, and Roopal Thakkar, will participate in the event. Investors can access a live audio webcast on AbbVie's Investor Relations website, with an archived version available later that day.
AbbVie aims to develop innovative medicines across various therapeutic areas, including immunology, oncology, neuroscience, and others. For more information, visit www.abbvie.com.
AbbVie will showcase 24 abstracts related to inflammatory bowel diseases (IBD) at the 18th ECCO Congress from March 1-4, 2023, in Copenhagen, Denmark. This includes six oral presentations focusing on SKYRIZI® (risankizumab) for Crohn's disease and RINVOQ® (upadacitinib) for ulcerative colitis. Notable presentations will cover efficacy outcomes and clinical responses from multiple studies, including ADVANCE, MOTIVATE, and FORTIFY. AbbVie emphasizes its commitment to advancing treatment options for IBD patients, with crucial analyses set to impact standards of care.
AbbVie announced a positive recommendation from the European Medicines Agency's CHMP for upadacitinib (RINVOQ) to treat adults with moderately to severely active Crohn's disease. This recommendation is based on results from two induction studies and one maintenance study, which showed significant improvements in clinical remission and endoscopic response compared to placebo. If approved by the European Commission, this will be the seventh indication for upadacitinib in the EU and the first JAK inhibitor for Crohn's disease. Upadacitinib's safety profile was consistent with previous findings, with no new significant risks identified.
AbbVie (NYSE: ABBV) has expanded its strategic collaboration with Capsida Biotherapeutics to develop genetic medicines targeting eye diseases. This collaboration enhances their existing partnership from 2021 focused on neurodegenerative diseases. Under the agreement, Capsida will receive $70 million which includes upfront payments and a potential equity investment. Capsida could earn up to $595 million in additional option fees and research milestones, along with royalties on future product sales. The partnership aims to leverage AbbVie's drug development expertise and Capsida's AAV engineering capabilities to advance three therapeutic programs.
The board of directors of AbbVie (NYSE: ABBV) has declared a quarterly cash dividend of $1.48 per share, payable on May 15, 2023, to stockholders of record by the close of business on April 14, 2023.
Since its inception in 2013, AbbVie has increased its dividend by over 270% and is recognized as a member of the S&P Dividend Aristocrats Index, which includes companies that have consistently raised dividends for at least 25 consecutive years.
AbbVie (NYSE: ABBV) reported full-year diluted EPS of $6.63, a 2.8% increase, and adjusted diluted EPS of $13.77, up 16.4%. Net revenues reached $58.054 billion, a 3.3% increase. Immunology portfolio revenues soared by 14.4%, totaling $28.924 billion, with Humira revenues at $21.237 billion. In contrast, hematologic oncology revenues fell 9.0% to $6.577 billion. For Q4, diluted EPS was $1.38, down 38.9%, while adjusted EPS rose 16.9% to $3.60. The company projects 2023 adjusted EPS guidance between $10.70 and $11.10, not accounting for acquired IPR&D expenses. AbbVie continues to enhance its portfolio and pipeline, including a major approval for Skyrizi in Crohn's disease.
Allergan Aesthetics, part of AbbVie (NYSE: ABBV), launched its 'Discover your 360°' initiative at the 24th IMCAS World Congress in Paris. This experience focuses on meeting aesthetic practitioners' and patients' evolving needs through innovative products and education. Key themes include Gender Inclusive Beauty and The End of Aging, discussed in various symposiums. Dr. Arthur Swift leads the opening symposium on Jan 28, with sessions featuring world-renowned experts. The event aims to enhance patient outcomes and supports practitioners with valuable insights. Allergan's commitment to aesthetics is reflected in its extensive product portfolio.
Allergan Aesthetics, part of AbbVie (NYSE: ABBV), announced the national launch of JUVÉDERM® VOLUX™ XC on January 18, 2023. This long-lasting hyaluronic acid filler addresses moderate to severe loss of jawline definition and is available for adults over 21. 40% of consumers are considering treatment for their jawline in the next year. Clinical trials showed high patient satisfaction, with results lasting up to 12 months. The JUVÉDERM Collection is the top dermal filler choice in the U.S., and providers prefer it over competitors. Allergan also offers the Allē loyalty program for rewards on treatments.